agilon health inc. stocks have been trading up by 11.19 percent amid strong growth outlook and improving healthcare partnership sentiment
What Traders Need To Know
- Management will appear at two healthcare and digital health conferences, speaking on ACO/value-based care and holding one-on-one meetings to strengthen industry and Wall Street visibility.
- A string of early-June Form 4 filings shows ongoing insider activity in AGL, though no details on trade size, pricing, or buy-versus-sell direction were disclosed.
- The lack of detail around insider transactions means these filings are weak as near-term trading signals, but they confirm active equity turnover among agilon health insiders.
- Recent price action shows AGL ripping from about $107 to $119 in a week, hinting at renewed momentum despite still-challenging profitability metrics.
Weekly Update Jun 22 – Jun 26, 2026: On Saturday, June 27, 2026 agilon health inc. stock [NYSE: AGL] is trending up by 11.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
agilon health (AGL) remains a structurally attractive, scale primary‑care enablement platform, but the fundamentals are weak versus Healthcare Providers & Services peers. Negative EBIT margin (~‑6%) and ROE (>‑100%) highlight immature profitability and execution risk despite strong multi‑year revenue CAGR (>30%). Balance sheet risk is contained: low leverage (total debt/equity ~0.2x), ample liquidity (current ratio ~1x, >$200M cash), and positive free cash flow (~$20M last quarter) support ongoing network build‑out without near‑term dilution.
Technically, AGL is in a short‑term uptrend after a sharp pivot: the weekly series shows a rebound from ~107 to 119 with a strong expansion day, signaling aggressive dip‑buying after a brief flush to 106–107. Intraday 5‑minute action (not shown numerically here) supports rising lows and strong closing prints, implying firm demand. The actionable trading level is $110: above it, long bias is warranted with upside to $125; a decisive close below $110 invalidates the setup.
More Breaking News
- TNMG Stock Pullback Puts TNL Mediagene On Watch
- MPT Stock Slides As Traders Weigh Debt, Dividend Risk
- BMNR Stock Pulls Back As Traders Gauge Risk
- NRXP Stock Builds Momentum As FDA Ketamine Catalyst Nears
Near‑term catalysts are moderate: management’s participation in value‑based care conferences should support sell‑side access and investor education but is not thesis‑changing. Recent Form 4 activity, absent size and direction, is noise. Versus healthcare and provider benchmarks, AGL trades at a substantial price‑to‑sales discount (~0.1x vs peers 1.5–2.0x) reflecting its loss‑making status but offering favorable risk‑reward for growth investors. I assign a 12‑month upside target of $125, with support at $110 and strong resistance near $130.
Quick Financial Overview
AGL (agilon health inc.) has shown sharp recent strength on the tape. Weekly data for late June shows price rebounding from around $106–$107 up to roughly $119, with the latest bar pushing to the top of that range. Intraday, a wide 5‑minute candle printed between about $104 and $119, which tells you liquidity stepped in aggressively on the upside. For short-term traders, that kind of range expansion often signals a shift from balance to momentum.
Under the hood, though, the business is still in cleanup mode. Profitability ratios are negative across the board, with EBIT margin around -6% and total profit margin also near -6%. Return on equity and return on assets are deeply negative, showing that agilon health inc. is not yet converting its $5.93B in revenue into efficient profits. On the plus side, the balance sheet is not over-levered: total debt to equity sits near 0.17, and current and quick ratios around 1 and 0.9 suggest a tight but manageable liquidity position.
Valuation tells a different story. With price to sales near 0.08, the market is assigning a low multiple to AGL’s revenue base, which can attract value-oriented traders looking for rerating setups. Cash flow is a relative bright spot: the most recent quarterly report shows positive operating cash flow of about $23.7M and free cash flow of roughly $20.6M, helped by modest capital spending. That said, negative cash flow per share and volatile historical P/E ranges warn that AGL remains a higher-risk, turnaround-style name rather than a stable compounder.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.